JP2016531852A - 非常に強力なグルココルチコイド - Google Patents

非常に強力なグルココルチコイド Download PDF

Info

Publication number
JP2016531852A
JP2016531852A JP2016516578A JP2016516578A JP2016531852A JP 2016531852 A JP2016531852 A JP 2016531852A JP 2016516578 A JP2016516578 A JP 2016516578A JP 2016516578 A JP2016516578 A JP 2016516578A JP 2016531852 A JP2016531852 A JP 2016531852A
Authority
JP
Japan
Prior art keywords
compound
alkyl
heteroaryl
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016516578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531852A5 (OSRAM
Inventor
フアチアン エリック シュー，
フアチアン エリック シュー，
ユアンゼン ヘ，
ユアンゼン ヘ，
カルステン メルシャー，
カルステン メルシャー，
ウェイ イー，
ウェイ イー，
ジンジン シ，
ジンジン シ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of JP2016531852A publication Critical patent/JP2016531852A/ja
Publication of JP2016531852A5 publication Critical patent/JP2016531852A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
JP2016516578A 2013-09-25 2014-09-25 非常に強力なグルココルチコイド Pending JP2016531852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361882444P 2013-09-25 2013-09-25
US61/882,444 2013-09-25
PCT/US2014/057497 WO2015048316A1 (en) 2013-09-25 2014-09-25 Highly potent glucocorticoids

Publications (2)

Publication Number Publication Date
JP2016531852A true JP2016531852A (ja) 2016-10-13
JP2016531852A5 JP2016531852A5 (OSRAM) 2017-11-02

Family

ID=52744465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516578A Pending JP2016531852A (ja) 2013-09-25 2014-09-25 非常に強力なグルココルチコイド

Country Status (9)

Country Link
US (1) US9975918B2 (OSRAM)
EP (1) EP3049089B1 (OSRAM)
JP (1) JP2016531852A (OSRAM)
KR (1) KR20160060688A (OSRAM)
CN (2) CN113845558A (OSRAM)
AU (1) AU2014324961A1 (OSRAM)
ES (1) ES2751457T3 (OSRAM)
HK (1) HK1222565A1 (OSRAM)
WO (1) WO2015048316A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532071A (ja) * 2016-10-14 2019-11-07 ヴァン アンデル リサーチ インスティテュート 非常に強力な糖質コルチコイドの構造およびデザインのための機構

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3319612T (pt) 2015-07-06 2021-08-24 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
CN113292623A (zh) 2015-07-06 2021-08-24 萨奇治疗股份有限公司 孕甾醇及其使用方法
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
BR112019008032A2 (pt) 2016-10-18 2019-09-03 Sage Therapeutics, Inc. oxiesteróis e métodos de uso dos mesmos
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
CN117024499A (zh) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 在2位引入亚甲基羟基的甾体化合物制备方法
WO2025157225A1 (zh) * 2024-01-24 2025-07-31 浙江柏拉阿图医药科技有限公司 一种高效力糖皮质激素化合物及其制备和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114473A1 (en) * 2009-04-03 2010-10-07 Astrazeneca Ab Novel steroidal[3,2-c]pyrazol derivatives with glucocorticoid activity
JP2010540612A (ja) * 2007-10-04 2010-12-24 アストラゼネカ・アクチエボラーグ グルココルチコイド活性を有するステロイド［３，２−ｃ］ピラゾール化合物
JP2012522766A (ja) * 2009-04-03 2012-09-27 アストラゼネカ・アクチエボラーグ グルココルチコイド活性を有するステロイド性［３，２−ｃ］ピラゾール化合物の新規アミド誘導体
JP2012530140A (ja) * 2009-06-16 2012-11-29 メルク・シャープ・アンド・ドーム・コーポレーション グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049813A (en) 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
EP1408042A4 (en) 2001-06-14 2005-02-02 Banyu Pharma Co Ltd NEW ISOXAZOLOPYRIDONE DERIVATIVES AND THEIR USE
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
US8173670B2 (en) 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540612A (ja) * 2007-10-04 2010-12-24 アストラゼネカ・アクチエボラーグ グルココルチコイド活性を有するステロイド［３，２−ｃ］ピラゾール化合物
WO2010114473A1 (en) * 2009-04-03 2010-10-07 Astrazeneca Ab Novel steroidal[3,2-c]pyrazol derivatives with glucocorticoid activity
JP2012522766A (ja) * 2009-04-03 2012-09-27 アストラゼネカ・アクチエボラーグ グルココルチコイド活性を有するステロイド性［３，２−ｃ］ピラゾール化合物の新規アミド誘導体
JP2012530140A (ja) * 2009-06-16 2012-11-29 メルク・シャープ・アンド・ドーム・コーポレーション グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532071A (ja) * 2016-10-14 2019-11-07 ヴァン アンデル リサーチ インスティテュート 非常に強力な糖質コルチコイドの構造およびデザインのための機構
JP7146750B2 (ja) 2016-10-14 2022-10-04 ヴァン アンデル リサーチ インスティテュート 非常に強力な糖質コルチコイドの構造およびデザインのための機構

Also Published As

Publication number Publication date
KR20160060688A (ko) 2016-05-30
HK1222565A1 (zh) 2017-07-07
WO2015048316A1 (en) 2015-04-02
US20160251393A1 (en) 2016-09-01
AU2014324961A1 (en) 2016-04-14
EP3049089A4 (en) 2017-08-09
CN113845558A (zh) 2021-12-28
EP3049089B1 (en) 2019-08-21
CN105744937A (zh) 2016-07-06
EP3049089A1 (en) 2016-08-03
ES2751457T3 (es) 2020-03-31
US9975918B2 (en) 2018-05-22
AU2014324961A8 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
JP2016531852A (ja) 非常に強力なグルココルチコイド
CN101454005B (zh) 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
JP5371988B2 (ja) 高血圧を処置するためのチアゾリジンジオン類似体
JP5634526B2 (ja) 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩
CN101454006B (zh) 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
TW200813010A (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
JP2010539171A5 (OSRAM)
JP2010539185A (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節因子
EP3152209B1 (en) Naphthyridinedione derivatives as suppressors of non-sense mutations
KR20130064742A (ko) 티아졸리딘디온 유사체
MX2008011870A (es) Terapias de combinacion de analogos de tiazolidindiona y agonistas glucocorticoides.
JP2022132464A (ja) 非常に強力な糖質コルチコイドの構造およびデザインのための機構
CN102947269B (zh) 噻唑烷二酮化合物的新的合成方法
CN103153991B (zh) 噻唑烷二酮化合物的合成方法
TW201623226A (zh) 化合物
HK40070300A (en) Highly potent glucocorticoids
WO1984001949A1 (fr) Derives de cephalosporine, leur procede de preparation et agent prophylactique de traitement contre les infections bacteriennes
CN107089955A (zh) 磺酰胺类衍生物及其制备方法和用途
HK40017057A (en) Structures and mechanism for the design of highly potent glucocorticoids
HK40017057B (zh) 用於设计高效力糖皮质激素的结构与机制
WO2025157225A1 (zh) 一种高效力糖皮质激素化合物及其制备和用途
CN103180304A (zh) 噻唑烷二酮化合物的新合成方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190322